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Abstract.  We have examined the functional signifi- 
cance of the organization of pre-mRNA splicing fac- 
tors in a speckled distribution in the mammalian cell 
nucleus. Upon microinjection into living cells of 
oligonucleotides or antibodies that inhibit pre-mRNA 
splicing in vitro, we observed major changes in the 
organization of splicing factors in vivo.  Interchromatin 
granule clusters became uniform in shape,  decreased 
in number, and increased in both size and content of 
splicing factors, as measured by immunofluorescence. 
These changes were transient and the organization of 
splicing factors returned to their normal distribution 
by 24 h following microinjection. Microinjection of 
these oligonucleotides or antibodies also resulted in a 
reduction of transcription in vivo,  but the oligonucleo- 
tides did not inhibit transcription in vitro. Control oli- 
gonucleotides did not disrupt splicing or transcription 
in vivo.  We propose that the reorganization of splicing 
factors we observed is the result of the inhibition of 
splicing in vivo. 
T 
RANSCRIPTION in mammalian cells by RNA polymer- 
ase II (Pol II) ~  results mostly in pre-messenger RNAs 
(pre-mRNAs) that contain intron sequences. These in- 
trons must be efficiently removed before the pre-mRNA  is 
transported  from the nucleus to the cytoplasm,  where it is 
translated. The removal of introns and the ligation of the re- 
maining exons is catalyzed by small nuclear ribonucleopro- 
tein particles (snRNPs) and a number of non-snRNP protein 
splicing factors (reviewed in Green,  1991; Guthrie,  1991). 
The pre-mRNAs produced by Pol II transcription contain 
conserved sequences at the 5' and 3' splice sites and a con- 
served region near the 3' splice site in the intron called the 
branchpoint.  These conserved sequences are recognized by 
snRNPs and non-snRNP  splicing factors as they assemble 
onto the pre-mRNA  to form a  spliceosome  (reviewed in 
Green,  1991; Guthrie,  1991). The assembly of snRNPs onto 
pre-mRNA to form a spliceosome occurs in an ordered path- 
way that culminates in the removal of intron sequences and 
ligation of exon sequences. A large number of experiments 
in yeast and mammalian systems have led to a model for the 
assembly of snRNPs onto pre-mRNA (reviewed  in McKeown, 
1993). First,  the U1  snRNP recognizes sequences at the 5' 
splice site in the pre-mRNA.  Next, the U2 snRNP binds to 
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the branchpoint region. Following the binding of the U1 and 
U2 snRNPs to the pre-mRNA,  a pre-assembled U4/U6/U5 
particle  associates  with  the bound  snRNPs  and the  pre- 
mRNA, with U5 interacting with 5' and 3' exon sequences. 
The U1 association is then destabilized,  U5 binds to the 5' 
end of  the intron, and the U4/U6 helix becomes partially un- 
paired resulting in the association of U6 with U2 forming a 
U2/U4/U6  complex. Finally, the U4 snRNP exits the com- 
plex leaving a U2/U6 complex with U2 bound at the branch- 
point and U6 associated with the 5' end of the intron.  This 
U2/U6-pre-mRNA  complex has been proposed to be a com- 
ponent of  the spliceosomal active site (Madhani and Guthrie, 
1992). It is this ordered  interaction of RNAs and proteins 
that enables the cellular  splicing machinery to remove in- 
trons from the pre-mRNA  correctly. 
In addition to the snRNPs,  a number  of protein  factors 
have been identified which are required for spliceosome as- 
sembly and splicing. For example, the protein factors U2AF 
(Ruskin et al.,  1988; Zamore and Green,  1989), SF1, and 
SF3 (Krgmer and Utans,  1991) are required for the binding 
of the U2 snRNP to the intron branchpoint and assembly of 
the pre-splicing  complex.  Two other non-snRNP  splicing 
factors, SF2/ASF (Krainer et al., 1990b) and SC-35 (Fu and 
Maniatis,  1990; Spector et al., 1991), are both required for 
the first step of  splicing and spliceosome assembly. SF2/ASF 
and SC-35 are also involved in 5' splice site selection of  alter- 
natively spliced pre-mRNAs (Ge and Manley, 1990; Krainer 
et al.,  1990a; Fu et al.,  1992). 
The snRNPs and some non-snRNP  splicing factors have 
been localized in the mammalian cell nucleus. The snRNPs 
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that has been termed the  speckled pattern  (Northway and 
Tan, 1972; Perraud et al., 1979; Lerner et al., 1981; Spector 
et al.,  1983;  Nyman et al.,  1986;  Verheijen et al.,  1986; 
Habets et al.,  1989). The speckled pattern is composed of 
20-50 intensely stained and irregularly shaped regions in the 
nucleus that are connected in places and set against a diffuse 
nuclear labeling (Spector,  1990). The use of antibodies to 
the trimethylguanosine cap of some of the snRNAs (Reuter 
et al., 1984) and of antisense probes to the snRNAs (Carmo- 
Fonseca et al., 1992; Huang and Spector, 1992) revealed that 
the RNA components of the snRNPs are also organized in 
the nucleus as a speckled pattern. Additionally, the essential 
non-snRNP splicing factor SC-35 displays a speckled distri- 
bution in the nucleus that colocalizes with snRNPs except 
that it does not give diffuse nuclear labeling (Fu and Mania- 
tis, 1990; Spector et al.,  1991). In the nucleus snRNPs and 
U2AF are also concentrated in coiled bodies, but SC-35 is 
not (reviewed in Lamond and Carmo-Fonseca,  1993). How- 
ever, the functional significance of the localization of some 
splicing factors in the coiled body remains to be elucidated. 
Electron microscopy with antibodies to snRNPs and SC- 
35 showed that the speckled pattern seen by immunofluores- 
cence corresponds to structures termed interchromatin gran- 
ules and perichromatin  fibrils (Spector et al.,  1983; Fakan 
et al.,  1984; Puvion et al.,  1984; Spector,  1990; Spector et 
al.,  1991). Interchromatin granules correspond to the larger 
intensely stained and irregularly shaped speckles seen by im- 
munofluorescence; they have little to no pH]uridine label- 
ing in their interior (Fakan and Bernhard,  1971; Fakan and 
Nobis,  1978) and may represent the sites of splicing factor 
storage and/or assembly. Perichromatin fibrils are found on 
the surface of and between interchromatin granule clusters; 
they  are  rapidly  labeled  with  [3H]uridine  (BacheUerie  et 
al.,  1975; Fakan et al.,  1976) and are thought to represent 
nascent pre-mRNA transcripts. It was proposed that snRNPs 
from interchromatin granule clusters move to the sites of ac- 
tive transcription  (perichromatin  fibrils)  to  splice nascent 
pre-mRNA transcripts (Jim6nez-Garcia and Spector, 1993). 
Numerous studies have used oligonucleotides and antibod- 
ies targeted to snRNAs to inhibit splicing in vitro (Padgett 
et al., 1983; Kr'~-ner et al., 1984; Black et al., 1985; Krainer 
and Maniatis, 1985; Berget and Robberson, 1986; Black and 
Steitz, 1986; Fabrizio et al., 1989; McPheeters et al., 1989; 
Fabrizio  and  Abelson,  1990;  Kr'~'ner,  1990;  McPheeters 
and Abelson, 1992). Oligonucleotides have also been micro- 
injected into Xenopus oocytes to inhibit splicing in vivo (Pan 
and Prives, 1988, 1989; Hanun et al., 1989; Pan et al., 1989; 
Hamm et al.,  1990; Vankan et al.,  1990,  1992; Prives and 
Foukal,  1991; Tsvetkov et al.,  1992). These in vitro and in 
vivo  studies  have  contributed  to  the  demonstration  that 
snRNAs are essential for splicing and have helped to identify 
specific regions of snRNAs that are important  for this nu- 
clear function.  The mechanism by which oligonucleotides 
inhibit splicing is via the degradation of the snRNAs through 
the ribonuclease H  activity found both in splicing extracts 
and in vivo (H~l~ne and Toulm~,  1990). Antibodies probably 
inhibit splicing by binding to the snRNAs and thus prevent- 
ing their interactions with the pre-mRNA and other snRNAs. 
In this study, we have investigated the effects of disruption 
of splicing in vivo on the organization of splicing factors in 
the mammalian cell nucleus. We have microinjected into liv- 
ing cells oligonucleotides or antibodies that inhibit splicing 
in vitro and then visualized the organization of splicing fac- 
tors in the nucleus. Following microinjection,  splicing fac- 
tors were reorganized  into interchromatin  granule clusters 
that decreased in number and became rounder and larger in 
size. The reorganization of splicing factors observed in the 
oligonucleotide-injected  cells  was  transient,  and  splicing 
factors returned to their normal distribution over time. The 
transcriptional  activity  of cells injected with oligonucleo- 
tides or antibodies that inhibit splicing in vitro was reduced. 
This did not result from a direct effect of the oligonucleotides 
on transcription, and appears to be a consequence of the dis- 
ruption of splicing.  Therefore, the disruption of splicing in 
vivo results in the reorganization of splicing factors to larger, 
rounder and fewer interchromatin granule clusters. The dis- 
ruption of splicing also results in the reduction of transcrip- 
tion possibly due to the temporal  and  spatial  coupling of 
transcription  and pre-mRNA splicing in vivo. 
Materials and Methods 
Oligonucleotides and Antibodies for Microinjection 
Oligodeoxynucleotides  were  synthesized  on a  DNA  synthesizer  (model 
380B; Applied Biosystems, Foster City, CA), dried down, and resuspended 
in 1 ml deionized water. The oligonucleotides  were then isolated from this 
solution with a Cts SEP-PAK cartridge  (Millipore Corp., Bedford,  MA), 
dried down,  and resuspended  in  100  t~l microinjection buffer  (10 rnM 
NaH2PO4, 70 mM KCI, pH 7.2).  The concentration of each oligonucleo- 
tide solution was calculated  by reading the OD260 and using the extinction 
coefficient  for each oligonucleotide.  The following oligonucleotides  were 
used: U1 Comp (5'-CTCCCCTGCCAGGTAAGTAT-Y), complementary to 
nucleotides  1-20 of U1 snRNA (Pan and Prives, 1988); UI-20 (5'-ATACTT- 
ACCTGGCAG~G-Y), identical to nucleotides 1-20 of U1 snRNA, U6 
Comp  (5'-CCTTCrCGCAGGGGCCATCd2TAATC-Y), complementary  to 
nucleotides  49-72 of U6 snRNA; Control (5"TCCGGTACCACGACG-39 
(Pan and Prives, 1988). 
Purified antibodies to the 2,2,7-trimethylguanosine cap (m3G) of snRNAs 
(Krainer,  1988) or goat anti-rat antibodies (Organon Teknika-Cappel, West 
Chester,  PA)  were applied  to a  G-25  column (PD-10;  Pharmacia Fine 
Chemicals, Piscataway, N  J) equilibrated with microinjection buffer. Frac- 
tions containing antibodies were pooled and concentrated with a Centricon 
30 microconcentrator (Amicon Corp., Danvers,  MA). 
Cell Culture and Microinjection 
HeLa cells were grown on photoetched glass coverslips (Bellco Glass, Inc., 
Vineland, NJ) in Dulbecco's modified Eagle's medium (DMEM) (GIBCO- 
BRL, Gaithersburg, MD) containing 10% fetal bovine serum and antibiotic- 
antimycotic (GIBCO-BRL).  Oligonucleotides  in microinjection  buffer were 
injected at a concentration of 150 #M with 15 mg/ml lysine fixable, Texas 
red-conjngated 70-kD dextrans (Molecular Probes Inc., Junction City, OR) 
into the cytoplasm of cells. The oligonucleotides  were free to move into the 
nucleus, whereas the dextrans were restricted to the cytoplasm by their size 
and thereby marked the cytoplasm of the injected cells. Antibodies in micro- 
injection buffer were injected at a concentration of I mg/ml with 1.5 mg/mi 
dextrans into the nucleus of cells. The antibodies and dextrans both stayed 
in the nucleus because of their size, with the dextrans marking the injected 
nuclei. 
The oligonucleotides  and antibodies were loaded into microinjection 
needles  (Femptotips,  Eppendorf; Brinkman Instruments Inc., Westhury, 
NY) and injected into cells using an Eppendorf Microinjector 5442 system 
paired with a Zeiss Axiovert 405M inverted microscope.  Following micro- 
injection cells were washed three times with DMEM at 37°C and returned 
to the incubator for the specified  amount of time. 
Immunofluorescence and Light Microscopy 
Cells were washed once with PBS, pH 7.4, and then fixed for 15 rain at room 
temperature with 2 % formaldehyde in PBS made fresh from paraformalde- 
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X-100 in PBS for 5 rain on ice. Cells were washed with PBS and then incu- 
bated with either monoclonal SC-35 ascites fluid (Fu and Maniatis,  1990) 
diluted  1:I,000  in PBS or purified monoclonal m3G antibody (Krainer, 
1988) diluted 1:1,000 in PBS for I h at room temperature. Cells were washed 
with PBS and then incubated with FITC-conjugated goat anti-mouse secon- 
dary antibodies (Organon Teknika) diluted 1:50 in PBS for 1 h at room tem- 
perature. Cells were washed with PBS and the coverslips were mounted on 
glass slides with 9:1  glycerol/PBS containing 0.1% p-pbenylenediamine 
buffered to pH 8.0 with 0.5 M carbonate/bicarbonate buffer (Johnson and 
Nogueira Araujo,  1981). Following microinjection of m3G antibodies, cells 
were fixed and permeabilized as described above and then incubated with 
rat anti-mouse antibodies (Organon Teknika) diluted 1:3 in PBS for 1 h at 
room temperature to mask any mouse antibody epitopes that may be recog- 
nized by the FITC-conjugated goat anti-mouse secondary antibodies. The 
m3Goinjected  cells were then labeled for SC-35 localization as described 
above. Cells prepared for immunoflnorescence  were photographed using ei- 
ther Kodak T-Max 3200 or Kodak Ektachrome 400 film using a  Nikon 
Microphot-FXA epifluorescence microscope equipped with a 60X, 1.4 NA 
objective lens. 
Cycloheximide Treatment 
The culture medium of HeLa cells grown as described above was removed 
and replaced with culture medium containing  100  #g/rrd cycloheximide 
(Sigma Immunochemicals, St. Louis, MO) for 2 h. Cells were then pre- 
pared for immunofluorescence  as described above and for light microscopic 
autoradiography as follows. 
Light Microscopic Autoradiography 
5,6-[3H]Uridine (Amersham Corp.) was added to a final concentration of 
50/zCi/ml in the culture medium of HeLa cells that were microinjected or 
treated with cycloheximide prior to fixation. Incorporation was carried out 
for 10 rain at 37°C and the cells were washed two times for 2 rain each with 
DMEM containing  1 m~/ml nonradioactive Uridine (Fluka AG, Buchs, 
Switzerland) at 37°C. Cells were then fixed and processed for immunofluo- 
rescence as described above. Prior to mounting, the coverslips were washed 
once with water, coated with fiford K.5D autoradiographic emulsion, and 
allowed to dry. Coverslips were stored in the dark at 40C for 7-21 d, and 
then the emulsion was developed (0.02  M  methylaminopbenol sulfate, 
0.04 M sodium sulfite, 0.02 M potassium thiocyanate) for 7 rain, washed 
twice with water for 2  rain each, fixed for 5 rain with Kodak fixer,  and 
washed with water.  The coverslips were then mounted as described above. 
Electron Microscopy 
For electron microscopy, HeLa cells were cultured and microinjected as de- 
scribed above. At 2 h after microinjection, cells were washed once with PBS 
and fixed in 2%  formaldehyde/2.5% glutaraldehyde in 0.1 M  cacodylate 
buffer pH 7.4. Cells were then washed three times for 5 rain each with 0.1 M 
cacodylate buffer and postfixed with 2 % osmium tetroxide in 0.1 M cacodyl- 
ate buffer.  Next, cells were washed three times for 5 rain each with water 
followed by en bloc staining for 1 h with 2 % uranyl acetate. The cells were 
then washed again with water, dehydrated with increasing percentages of 
ethanol, and infiltrated overnight with a 50:50 mixture of 100% ethanol and 
Epon-Araldite, The coverslips were then embedded in 100% Epon-Araldite 
and polymerized at 60°C overnight. The glass coverslips were then removed 
with hydrofluoric acid and the injected areas were cut out and reembedded 
for ultramicrotomy. Thin sections were cut with a diamond knife (Diatome 
Ltd., Bierme, Switzerland) using a Reichert-Jung Ultracut E  ultramicro- 
tome. Sections ~90 nm in thickness were picked up on 300-mesh copper 
grids and stained with 2% uranyl acetate and lead citrate (Reynolds, 1963) 
and viewed with a Hitachi H-7000 transmission electron microscope oper- 
ated at 75 kV. 
In Vitro Splicing Assay 
For  the  in  vitro  splicing assay,  the  oligonucleotides were  purified by 
preparative electrophoresis on 20 % acrylamide/7 M urea gels and the DNA 
was recovered from the excised and crushed gel slices by elution overnight 
in 1 ml deionized water. Gel fragments were removed with a 0.22 #m filter 
and the DNA in the remaining solution was isolated with a Cts SEP-PAK 
cartridge, dried down, and resnspended in  100  t~l diethyl pyrocarbonate 
treated water. The plasmid pSP64-HBA6 (Krainer et al., 1984),  containing 
the human B-globin gene, was linearized with BamHI. 32P-labeled, capped 
pre-mRNA substrates were prepared by runoff transcription with SP6 RNA 
polymerase as described (Krainer and Maniatis,  1985;  Mayeda and Oh- 
shima, 1988).  ~globin pre-mRNA (20 fmol), 10 ~1 HeLa cell nuclear ex- 
tract, and each oligonucleotide (300 pmol, final concentration 12/~M) was 
pre-incubated in 17/~1 with 20 mM Hepes-KOH (pH 7.3) at 30"C for 15 
min prior to the splicing reaction. For the splicing reaction, ATP/creatine 
phosphate, MgC1, KC1, and polyvinyl alcohol were added to a final volume 
of 25/~1 and incubated at 30"C for 3 h as described (Mayeda et al., 1990). 
RNA  products wore analyzed by electrophoresis on a  5.5%  polyacryl- 
amide/7  M  urea  gel  followed by  autoradiography with an  intensifying 
screen at  -70°C. 
In Vitro Transcription Assay 
For the in vitro transcription assay the oligonucleotides were purified in the 
same manner as was described for the in vitro splicing assay. A G-less cas- 
sette construct containing the adenovirus 2 major late promoter (Sawadogo 
and Roeder, 1985; Lobo et al., 1992) was used in a 25/~1 transcription reac- 
tion containing the following components: 60 mM KCI, 20 mM Hepes (pH 
7.9),  9 mM MgCI2,  12% glycerol, 1 mM spermidine, 1 mM T-O-methyl- 
GTP, 0.5/~g of supercoiled template, 0.5 U of ribonucleas¢ T1, and 4 #1 
(100/~g)  of whole cell extract. To this was added either water, 2/zg/ml 
a-amanitin, or oligonucleotide (300 pmol, final concentration 12 t~M). The 
reactions were incubated at 30°C for 1 h and terminated by the addition of 
stop mix and processed as described (Sadowski et al., 1993). Preincubation 
of the oligonucleotides with the extract before the addition of nucleotides 
made no difference in the levels of transcription observed. 
Results 
Oligonucleotides Targeted to snRNAs Inhibit Splicing 
In Vitro 
The  assembly  of snRNPs  onto  a  pre-mRNA  to  form  a 
spliceosome,  within  which introns are removed,  requires 
specific RNA/RNA interactions. One of the first RNA/RNA 
interactions involved in spliceosome assembly and splicing 
is the association of the U1 snRNP with the pre-mRNA. The 
U1 snRNA has been shown to bind specifically to the pre- 
mRNA conserved sequences at the 5' splice site and to the 
conserved AG at the 3' splice site to set up interactions be- 
tween other snRNPs and the pre-mRNA (Reich et al., 1992; 
Wassarman and Steitz, 1992).  To disrupt these interactions 
and inhibit splicing, an oligonucleotide was synthesized that 
was  complementary to the 5' end of the U1  snRNA (U1 
Comp). This oligonucleotid¢ is similar to oligonucleotides 
used  to  inhibit  splicing  in  amphibian  oocytes  (Pan  and 
Prives,  1988;  Pan et al.,  1989;  Prives and Foukal,  1991; 
Jantsch and Gall,  1992;  Tsvetkov et al.,  1992) and should 
bind to U1 snRNA and prevent its association with the pre- 
mRNA by causing cleavage at its 5' end. When this oligonu- 
cleotide was added to an in vitro splicing reaction, it in- 
hibited  the  splicing  of a  /3-globin  pre-mRNA  substrate 
whereas a control oligonucleotide (Control) did not (Fig. 1, 
compare lanes 3 and 2). 
The next oligonucleotide we used to disrupt splicing was 
identical to the 20 nucleotides at the 5' end of the U1 snRNA 
(U1-20).  This  oligonucleotide  should  compete  with  U1 
snRNPs for binding to the pre-mRNA and therefore disrupt 
splicing. This oligonucleotide is identical to the 5' end of the 
U1 snRNA so it may also compete with the U5 snRNP (New- 
man and Norman, 1992; Wassarman and Steitz, 1992) and 
U6 snRNP (Madhani and Guthrie, 1992; Sawa and Abelson, 
1992;  Sawa  and  Shimura,  1992;  Wassarman and  Steitz, 
1992),  which have also been shown to interact at, or near, 
the  5' and 3' splice  sites.  When this oligonucleotide was 
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1990, 1992). These results demonstrate that the oligonucleo- 
tides targeted to disrupt splicing can specifically inhibit the 
processing of a pre-mRNA substrate in vitro. 
Figure 1.  Oligonucleotides complementary  to  snRNAs or pre- 
mRNA inhibit splicing of a pre-mRNA substrate in vitro. In vitro 
splicing of a fl-globin pre-mRNA containing the first two exons 
and first intron was analyzed following preincubation of the HeLa 
nuclear  extract with oligonucleotides. The oligonucleotides that 
were complementary to snRNAs or pre-mRNA inhibited the splic- 
ing of  the/~-globin pre-mRNA substrate (lanes 3-5). A control oli- 
gonucleotide does not  inhibit the  splicing of the/%globin pre- 
mRNA (lane 2). The pre-mRNAs in lanes 3-5 are partially cleaved 
to various extents, most likely by endogenous ribonuclease H in 
combination with other ribonucleases. Some of the resulting frag- 
ments fortuitously co-migrate with exon 1 or excised intron RNAs. 
Lane 1, water added in same volume as oligonucleotides. Lane 2, 
Control oligonucleotide. Lane 3, UI Comp oligonucleotide com- 
plementary to 5' end of U1 snRNA. Lane 4, U6 Comp oligonucleo- 
tide complementary to nucleotides 49-72 of U6 snRNA. Lane 5, 
U1-20 oligonucleotide identical to the 5' end of the U1  snRNA. 
Lane  M,  32p-labeled pBR322/HpaII  DNA  size  markers  with 
length in nucleotides. ~--globin  pre-mRNA and its splicing prod- 
ucts are schematically represented on the right side. 
added to an in vitro splicing reaction, it also inhibited the 
splicing of a/3-globin pre-mRNA substrate (Fig. 1, compare 
lanes 5  and 2). 
Another RNA/RNA interaction that is important for splic- 
ing is the association of U6 snRNA with U4 snRNA (Bring- 
mann et al.,  1984; Hashimoto and Steitz,  1984;  Rinke et 
al.,  1985)  and  U2  snRNA  (Madhani  and  Guthrie,  1992; 
McPheeters and Abelson,  1992). To disrupt these interac- 
tions and inhibit splicing, we synthesized an oligonucleotide 
complementary to the region of U6 that binds to U4 and U2 
snRNA (U6 Comp). As for the U1 Comp and U1-20 oligonu- 
cleotides, the U6 Comp oligonucleotide inhibited the splic- 
ing of a/3-globin pre-mRNA substrate (Fig. 1, compare lanes 
4 and 2). Oligonucleotides that target different regions of U6 
snRNA for ribonuclease H degradation have previously been 
Microinjection of Oligonucleotides or Antibodies that 
Inhibit Splicing In Vitro Results in Reorganization of 
Splicing Factors In Vivo 
To determine what effect the disruption of splicing in vivo 
has on the organization of splicing factors in the nucleus we 
microinjected the oligonucleotides that inhibited splicing in 
vitro into HeLa cells. The oligonucleotides were co-injected 
into the cytoplasm of living cells with fixable, Texas red- 
conjugated, 70-kD dextrans.  The dextrans mark the cyto- 
plasm of injected ceils, whereas the small oligonucleotides 
are free to diffuse into the nucleus. At 2 h after microinjec- 
tion, the cells were fixed and an antibody directed against the 
splicing factor SC-35 was used to examine the nuclear or- 
ganization of this splicing factor. For each of the oligonu- 
cleotides that inhibited splicing in vitro, U1 Comp (Fig. 2 a), 
U1-20 (Fig. 2 b), and U6 Comp (Fig. 2 c), there was a reor- 
ganization of SC-35 compared to the noninjected cells in the 
same field. The irregularly shaped speckles became larger, 
rounded,  and  decreased in number with a  concurrent in- 
crease in their fluorescent intensity. In addition, the connec- 
tions that are normally observed between speckles were ab- 
sent. Microinjection of the Control oligonucleotide that did 
not inhibit splicing in vitro had no effect on the organization 
of SC-35 (Fig. 2  e). 
Since the  oligonucleotides were microinjected into  the 
cytoplasm of cells it is possible that the experimental oligo- 
nucleotides may exert their effects there as well. The snRNAs 
are known to assemble with their respective snRNP proteins 
in the cytoplasm (Zieve and Sauterer, 1990). Therefore, the 
U1 Comp oligonucleotide may prevent the import of new U1 
snRNA into the nucleus because of the loss of the m3G cap 
at its 5' end needed for nuclear import (Hamm et al.,  1990; 
Jantsch and Gall,  1992). 
The changes observed in splicing factor organization fol- 
lowing microinjection of oligonucleotides targeted to disrupt 
splicing were transient. At 5-6 h following microinjection of 
the U1 Comp oligonucleotide the localization of SC-35 be- 
gan to return to normal and by 24 h most of  the microinjected 
cells had reverted to the typical nuclear distribution of SC-35 
(Fig. 2f). The return of SC-35 to its normal distribution over 
time was also observed following microinjection of the other 
oligonucleotides that  inhibited  splicing  in  vitro and  reor- 
ganized SC-35 (data not shown). This reversion can be ex- 
plained by the fact that microinjected oligonucleotides are 
eventually degraded in vivo (Pan and Prives, 1988) and that 
new snRNA synthesis and snRNP assembly will occur. 
The reorganization of splicing factors is not restricted to 
microinjected oligonucleotides that inhibit splicing. Micro- 
injection into the nucleus of cells of antibodies to the m3G 
cap of snRNAs that inhibit splicing in vitro (KrLrner et al., 
1984) also resulted in the reorganization of SC-35 within the 
nucleus (Fig. 2 d) similar to that observed with the oligonu- 
cleotides.  The speckles again rounded up,  became larger, 
and decreased in number.  In addition, there was a loss of 
connections between speckles that are normally observed. 
Microinjection of a control goat anti-rat antibody, however, 
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nucleotides were microinjected into the cytoplasm of HeLa cells with a Texas red-labeled dextran to mark the cytoplasm of the injected 
cells. At 2 h after microinjection the cells were processed for immunofluorescence of the splicing factor SC-35 (green)  as described in 
Materials and Methods. Cells microinjected with the oligonucleotides  that inhibit splicing in vitro, U1 Comp (a), U1-20 (b), and U6 Comp 
(c), display a reorganization of splicing factors to large, rounded structures in the nucleus. The Control oligonucleotide (e) that does not 
inhibit splicing in vitro, did not change the organization of SC-35 when injected into cells. At 24 h after microinjection the reorganization 
seen with the U1 Comp oligonucleotides was no longer apparent in the injected cells (f) which display a normal distribution of SC-35. 
Nuclear microinjection of antibodies against the m3G cap of snRNAs and Texas red-labeled dextrans (d) also resulted in the reorganiza- 
tion of SC-35 similar to that observed with the oligonucleotides. In d only SC-35 labeling (green)  is shown and the injected nuclei are 
indicated with arrows. Bar, 20/~m. 
O'Keefe et al. Disruption of Pre-mRNA Splicing In Vivo  253 Figure 3. Microinjection of oligonucleotides that inhibit splicing in vitro results in the reorganization of snRNAs in vivo. The U1 Comp 
oligonucleotide was microinjected into the cytoplasm of HeLa ceils with a Texas red-labeled dextran to mark the cytoplasm of the injected 
cells. At 2 h after microinjection the cells were processed for immunofluorescence to reveal the localization of snRNAs as described in 
Materials and Methods. snRNAs detected with antibodies to their m3G cap (a) are reorganized to rounded structures within the nuclei 
of oligonucleotide injected cells that are marked in their cytoplasm with the Texas red-labeled dextrans (b). The oligonucleotide injected 
cells have a different nuclear organization of snRNAs than the noninjected ceils in the same field. This reorganization is similar to that 
observed when oligonucleotides that inhibit splicing were microinjected into cells and labeled with antibodies to SC-35  (Fig. 2). Bar, 
20/zm. 
did not affect the organization of splicing factors (see Fig. 6, 
b  and f). 
The effects observed within the nucleus following microin- 
jection  of oligonucleotides that  inhibit  splicing  were  not 
limited only to SC-35. If cells were microinjected with the 
U1 Comp oligonucleotide (Fig. 3) and then processed for im- 
munofluorescence with an antibody specific to the m3G cap 
of snRNAs, a reorganization of snRNAS  was also observed 
(Fig. 3). This reorganization of snRNAS was similar to that 
observed with SC-35 following oligonucleotide injection. A 
reorganization of snRNAS was also observed with the other 
oligonucleotides that inhibit splicing, but not the Control oli- 
gonucleotide (data not shown). 
To  determine the  nature  of the  enlarged  and  rounded 
speckles, we prepared cells microinjected with the U6 Comp 
oligonucleotide for electron microscopy. Visualization of  oli- 
gonucleotide injected cells by electron microscopy revealed 
that these rounded speckles corresponded to enlarged inter- 
chromatin granule clusters (Fig.  4  a)  as compared to the 
smaller  and  irregularly  shaped  interchromatin  granule 
clusters observed in non-injected cells or cells microinjected 
with the Control oligonucleotide (Fig. 4  b). These results, 
and the immunofluorescent results described above, indicate 
that  the  disruption  of  splicing  in  vivo  by  two  different 
methods caused a reorganization of splicing factors to larger 
and rounder interchromatin granule clusters. 
Transcription is Reduced in Cells Microinjected with 
Oligonucleotides or Antibodies that Inhibit Splicing 
In Vitro 
The reorganization of splicing factors seen following micro- 
injection of oligonucleotides or antibodies that disrupt splic- 
ing is similar to the changes observed when cells are treated 
with inhibitors of transcription (Spector et al., 1983; Carmo- 
Fonseca et al., 1992). To investigate what effects microinjec- 
tion of the oligonucleotides or antibodies had on the tran- 
scriptional activity of cells,  we added  [3H]uridine to  the 
culture medium prior to fixation. Cells were then processed 
for immunofluorescence of splicing factors, coated with an 
autoradiographic emulsion, and developed for light micro- 
scopic autoradiography at various times following coating. 
As seen in Fig. 5, microinjection of either the U6 Comp oli- 
gonucleotide (Fig. 5, a  and b) or m3G antibodies (Fig. 5, c 
and d) that disrupt splicing reduced the transcriptional activ- 
ity of the injected cells (arrows). This was observed as fewer 
autoradiographic grains over the injected cells as compared 
to the non-injected cells in the same field. The U1 Comp and 
U1-20 oligonucleotides also reduced transcription in the in- 
jected cells (data not shown). The control oligonucleotides 
(Fig. 6, a, c, and e) or control goat anti-rat antibodies (Fig. 
6, b, d, and  f), however, did not affect the transcriptional ac- 
tivity of injected cells, as compared to non-injected cells in 
the same field. 
The reduction in transcription could result either from a 
direct inhibitory effect of the oligonucleotides and antibod- 
ies,  or from the disruption of splicing.  To distinguish be- 
tween these two possibilities, we added the oligonucleotides 
to an in vitro transcription reaction to determine whether 
they had any effect on transcription by Pol II. Addition of 
both specific and control oligonucleotides to an in vitro tran- 
scription reaction programmed with the adenovirus major 
late (AdML) promoter did not have any major effect on tran- 
scription (Fig. 7, lanes 3-6). There is no significant differ- 
ence in the amount of transcription product made when the 
U1 Comp or the Control oligonucleotides were added to the 
reaction (Fig.  7,  compare lanes 3  and 4).  Although there 
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ule clusters become enlarged 
and uniform in shape follow- 
ing microinjection of oligonu- 
cleotides  that inhibit splicing. 
Oligonucleotides  that  inhibit 
splicing in vitro were microin- 
jected into cells,  which were 
then  processed  for  electron 
microscopy  as  described  in 
Materials  and Methods. Inter- 
chromatin granule clusters (ar- 
rows) became larger, rounded, 
and  fewer  in  number  fol- 
lowing  microinjection  of the 
U6 Comp oligonucleotide  (a) 
compared  to  interchromatin 
granule  clusters  in cells  mi- 
croinjected  with  the  Control 
oligonucleotide  (b).  The  en- 
larged interchromatin  granule 
cluster  observed  in  the  U6 
Comp injected cells (a) corre- 
sponds to the large,  rounded, 
structures  that were observed 
by immunofluorescence in the 
oligonucleotide  injected  cells 
(Figs.  2 and 3).  Bar,  1 #m. 
Figure  5.  Microinjection  of 
oligonucleotides  or antibodies 
that inhibit  splicing  results  in 
a  reduction of the  transcrip- 
tional  activity of cells.  HeLa 
cells were microinjected with 
the U6 Comp oligonucleotide 
(a and b) or antibodies against 
the  m3G  cap  of snRNAs  (c 
and d).  At 2 h after injection 
the  cells  were  labeled  with 
[3H]uridine  to monitor  their 
transcriptional  activity (b and 
d)  and  the  cells  were  pro- 
cessed for immunofluorescence 
of SC-35 (a and c) and light 
microscopic autoradiography 
as  described  in  Materials 
and Methods. Autoradiography 
shows  that both oligonucleo- 
tides  (b)  and  antibodies  (d) 
that inhibit splicing and caused 
a reorganization of splicing fac- 
tors (a and c, arrows), also dis- 
rupt  transcription  in  the  in- 
jected cells (b and d, arrows). 
The cells shown in this figure 
are representative  of many in- 
jected  cells  that  all  had  de- 
creased  transcriptional  activ- 
ity. Bar,  20 #m. 
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oligonucleotides  or antibodies  does 
not change the transcriptional  activ- 
ity ofceUs. HeLa cells were microin- 
jeered in the cytoplasm  with the Con- 
trol oligonucleotide (a,  c, and e) or 
in the  nucleus  with  a  control goat 
anti-rat antibody (b,  d,  and f).  At 
2 h after injection the cells  were la- 
beled  with  [3H]uridine  to  monitor 
transcriptional  activity (c and d) and 
processed  for  immunofluorescence 
of SC-35 (a and b) and light micro- 
scopic autoradiography as described 
in Materials  and Methods.  Microin- 
jection of the  Control oligonuclco- 
tide (a) or a control goat anti-rat an- 
tibody  (b)  does  not  change  the 
localization ofSC-35. The transcrip- 
tional activity of  the Control oligonu- 
cleotide  (c)  or  the  control  goat 
anti-rat antibody (d) injected cells is 
also  unchanged.  Cells  were  co- 
injected  with Texas red-labeled dex- 
trans to mark the oligonucleotide-  (e) 
and antibody- 0  r) injected cells. Bar, 
20/~m. 
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that inhibit splicing do not in- 
hibit RNA polymerase II tran- 
scription  in vitro.  The tran- 
scription from the adenovirus 
2 major late (AdML)  promoter 
was monitored following ad- 
dition of oligonucleotides.  The 
oligonucleotides did  not  sig- 
nificantly affect  the generation 
of  transcription products from 
the AdML promoter. In contrast, the addition of a known RNA Pol 
II inhibitor, oe-amanitin, abolished all transcription from the AdML 
promoter. Lane 1, water added in same volume as oligonucleotides. 
Lane 2, a-amanitin (2 #g/ml).  Lane 3, Control oligonucleotide. 
Lane 4, U1 Comp oligonucleotide. Lane 5, U1-20 oligonucleotide. 
Lane 6, U6 Comp oligonucleotide. 
does appear to be some decrease in transcription when the 
U1-20  and  U6  Comp  oligonucleotides are  added  (Fig.  7, 
lanes 5 and 6), this is a small decrease as compared to the 
addition of a known transcription inhibitor, ot-amanitin,  that 
resulted in no transcription products at all (Fig. 7, lane 2). 
However, when each of the experimental oligonucleotides 
were microinjected into cells there was a dramatic decrease 
in  transcriptional activity.  Therefore, to the extent that in 
vitro transcription faithfully mimics in vivo transcription, 
the inhibition of the latter by microinjected oligonucleotides 
was probably an indirect phenomenon. 
Transcription and Splicing May Be Coordinated 
In V~vo 
The results described above suggest that the disruption of 
splicing reduces transcription in the injected cells. There are 
at least two possible ways by which this may occur. One pos- 
sibility is that splicing and transcription are directly linked 
in vivo. Therefore, the disruption of splicing might disrupt 
transcription. The other possibility is that the disruption of 
splicing results in the inability of the cell to synthesize one 
or more labile transcription factors from pre-mRNAs that 
must be spliced. The second possibility was tested by inhibit- 
ing translation in the cell to determine if labile proteins are 
required for transcription to occur. We therefore treated cells 
with cycloheximide for 2 h and then monitored the transcrip- 
tional  activity  of the  cells  by  [3H]uddine  incorporation. 
Treaanent of  cells with cycloheximide  did not affect the orga- 
nization of splicing factors (Fig.  8  a)  or transcription by 
RNA Pol II or Pol 1/I (Fig. 8 b). This was revealed by no ap- 
parent decrease in the level of autoradiographic grains in the 
non-nucleolar regions of the nucleus. RNA Pol I transcrip- 
tion, which is restricted to the ribosomal RNA genes in the 
nucleoli, however, appeared to be reduced, as seen by the 
presence of fewer autoradiographic grains over the nucleoli 
(Fig. 8 b). These results indicate that a labile factor or factors 
are required for RNA Pol I transcription in the nucleoli. This 
is in accordance with previous biochemical studies that have 
shown that cycloheximide treatment reduces the transcrip- 
tion  of ribosomal  RNA  in  the  nucleolus  (Higashi  et  al., 
1968; Willems et al., 1969). Pol II and Pol III transcription, 
however, are not dependent on highly labile factors. There- 
fore, transcription by these factors may be disrupted in the 
injected cells because splicing and transcription are tightly 
coupled. 
Discussion 
We have demonstrated that when oligonucleotides or anti- 
bodies that inhibit splicing in vitro are introduced into living 
cells by microinjection, there is a reorganization of splicing 
Figure 8. Cycloheximide treatment reveals that a labile factor(s) is not needed for RNA Pol II transcription. Cells were treated with cyclo- 
heximide for 2 h, labeled with [3H]uridine to monitor transcriptional activity (b) and processed for immunofluorescence of SC-35 (a) 
and light microscopic autoradiography as described in Materials and Methods. The localization of SC-35 (a) does not appear to be changed 
by this treatment. The transcriptional activity of cycloheximide-treated cells (b) is unchanged in the non-nucleolar regions of the nucleus 
(Pol II and Pol III transcription).  The nucleolar regions of the nucleus, however, have reduced transcriptional activity indicating that a 
labile factor(s) is needed for RNA Pol I transcription.  Bar, 20 #m. 
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large, rounded, structures in the nucleus that corresponded 
to enlarged interchromatin granule clusters. The reorganiza- 
tion of splicing factors following oligonucleotide microinjec- 
tion was transient and splicing factors returned to their nor- 
mal distribution over time.  The transcriptional activity of 
ceils microinjected with oligonucleotides or antibodies that 
inhibit splicing in vitro was reduced; however, this may not 
be a direct effect of the oligonucleotides or the antibodies on 
transcription. We propose that the reorganization of splicing 
factors to enlarged interchromatin granule clusters may rep- 
resent the inhibition of pre-mRNA splicing in vivo. 
Organization of Splicing Factors within the Nucleus 
Studies on the organization of splicing factors by electron 
microscopy have pointed to a model in which splicing factors 
in the nucleus make up, or are associated with, three struc- 
tural 'components of the nucleus. These components are the 
interchromatin granule clusters, perichromatin fibrils, and 
coiled bodies (reviewed in Spector, 1993). It is now thought 
that the interchromatin granule clusters are the sites of splic- 
ing factor storage and/or assembly, whereas the perichroma- 
tin fibrils represent the actual nascent pre-mRNA transcripts 
to  which  splicing  factors  from  interchromatin  granule 
clusters have moved to carry out splicing (reviewed in Spec- 
tor, 1993).  The role of coiled bodies in nuclear function is 
less clear because of their absence in some cells (Spector et 
al.,  1992)  and their protein composition (reviewed in La- 
mond and Carmo-Fonseca, 1993; Brasch and Ochs, 1992). 
We have shown that the reorganization of splicing factors, 
observed following microinjection of oligonucleotides or an- 
tibodies targeted to disrupt splicing, is to the interchromatin 
granule clusters.  This  may result  from the  loss  of peri- 
chromatin  fibrils  (i.e.,  nascent transcripts)  following the 
inhibition of splicing and transcription. These interchroma- 
tin granule clusters, which are irregularly shaped and fairly 
numerous in normal cells, become enlarged, rounded, and 
decrease in number.  We propose that this morphological 
change of the interchromatin granule clusters may represent 
the  return  of  splicing  factors  from  perichromatin  fibril 
regions (i.e.,  connections between speckles) to their sites 
of storage  and/or assembly  (i.e.,  interchromatin granule 
clusters), until splicing is resumed, The enlargement of in- 
terchromatin granule clusters could result from the accumu- 
lation of splicing factors while their reduction in number 
may result from the association of interchromatin granule 
clusters with one another. Visualization of splicing factors 
hours after injection of the oligonucleotides indicates that 
these enlarged interchromatin granule clusters are only tran- 
sient structures. It appears that when splicing resumes, the 
interchromatin granule clusters are reduced in size, most 
likely reflecting the movement of splicing factors back to 
perichromatin fibrils, where they are needed to splice na- 
scent pre-mRNAs. It is, therefore, likely that when splicing 
is disrupted in vivo, the cell responds by moving splicing fac- 
tors back to the regions of storage and/or assembly until 
splicing is resumed. This suggests a dynamic organization of 
splicing factors in the nuclei of transcriptionally active cells. 
A similar reorganization of splicing factors to larger inter- 
chromatin granule clusters  in the nucleus has previously 
been observed following herpes simplex virus infection of 
cells (Martin et al.,  1987)  as well as in many pathological 
situations (reviewed in Fakan and Puvion,  1980).  It was 
speculated by Martin et al. (1987) that this reorganization in 
infected cells resulted from the partial inactivation of host 
pre-mRNA splicing. Our work is in concordance with this 
previous study and extends it by demonstrating that microin- 
jection  into  cells  of oligonucleotides  which  inhibit  pre- 
mRNA splicing in vitro results in a reorganization of splicing 
factors to larger interchromatin granule clusters. 
Associations Between Splicing and Transcription 
When we monitored transcription in cells that were injected 
with oligonucleotides or antibodies that inhibit splicing in 
vitro, in addition to the reorganization of splicing factors we 
observed a reduction in the transcriptional activity of these 
cells. The control oligonucleotides or antibodies, however, 
did not affect transcription in the cells into which they were 
injected. In Xenopus oocytes, transcription of microinjected 
SV-40 DNA (Pan and Prives, 1988, 1989; Pan et al., 1989; 
Prives  and  Foukal,  1991) or  DNA  for  mutant  snRNAs 
(Hamm et al.,  1989;  Pan and Prives,  1989;  Hamm et al., 
1990; Vankan et al., 1990; Vankan et al., 1992) occurred fol- 
lowing the inhibition of splicing with oligonucleotides tar- 
geted to snRNAs. In another study when any oligonucleotide 
was microinjected into Xenopus or Notophthalmus oocytes, 
cytological changes, disappearance of some or all of the B 
snurposomes, and shutdown of endogenous Pol II transcrip- 
tion were initially observed (Tsvetkov et al.,  1992).  How- 
ever,  at later times after microinjection, transcription re- 
sumed in these oocytes in the  absence of U2  snRNA as 
evaluated by Northern analysis and in situ hybridization. 
From these results it was concluded that splicing was not re- 
quired for transcription on lampbrush chromosome loops 
(Tsvetkov et al.,  1992), 
In HeLa cells we observed changes in the organization 
of splicing factors and in Pol II transcription with oligo- 
nucleotides that inhibit splicing but not with control oligonu- 
cleotides. In addition, in the cells injected with the oligonu- 
cleotides that inhibit splicing, we observed an increase in the 
size of the interchromatin granule clusters. We believe inter- 
chromatin granule clusters are the sites of splicing factor 
storage and/or assembly. Similarly, the B snurposomes pres- 
ent in amphibian oocyte germinal vesicles have been pro- 
posed to be the sites of splicing factor assembly, storage or 
recycling as well (Wu et al., 1991). However,  the reduction 
in number or disappearance of the B snurposomes observed 
in the Xenopus and Notophthalmus oocytes following oligo- 
nucleotide injection is in contrast to our observation of an 
increase in size of interchromatin granule clusters. This con- 
trast may reflect the fact that cultured mammalian somatic 
nuclei and amphibian oocyte nuclei are organized differently 
and that interchromatin granule clusters and B snurposomes 
may be structurally different although they contain many of 
the same constituents. 
We found little effect of the oligonucleotides on the tran- 
scription of the AdML promoter, as compared to the transcrip- 
tion inhibitor c~-amanitin, when we monitored transcription 
in vitro uncoupled from splicing. This suggests that the re- 
duction of Pol II transcription we observed in vivo with oli- 
gonucleotides that inhibit splicing may be a consequence of 
the inhibition of splicing rather than the direct disruption of 
transcription. It is possible that when the cell detects that 
splicing is disrupted, splicing factors return to their sites of 
storage and/or assembly (i.e., interchromatin granule clus- 
ters) and transcription is shut down until splicing is restored. 
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cannot be processed and would therefore accumulate in the 
nucleus. It is likely, therefore, that splicing and transcription 
may be coordinated within the nucleus with the status of one 
function affectin~ the other. 
A number of researchers have proposed that splicing oc- 
curs cotranscriptionally and that splicing and transcription 
are  coordinated  (Sass  and  Pederson,  1984;  Fakan  et  al., 
1986;  Beyer and Osheim,  1988;  LeMaire and  Thummel, 
1990;  Huang  and Spector,  1991;  Xing et al.,  1993).  The 
results  we present here are  in agreement  with these pro- 
posals.  Recent  studies  using  adenovirus  serotype 2  infec- 
tion and transient transfection of a plasmid containing a por- 
tion of the/3-tropomyosin gene into HeLa cells showed that 
splicing factors move to new transcription  sites from storage 
and/or assembly sites (Jim6nez-Garcfa  and Spector,  1993). 
From these data a model has been proposed in which tran- 
scription and splicing are coordinated in the nucleus by a 
recruiting mechanism. In this model, splicing factors are as- 
sociated with specific storage and/or assembly sites in the 
nucleus and are recruited to the active sites of transcription 
by another factor or chaperone molecule before, or at,  the 
initiation of transcription.  Our experiments corroborate this 
model. This idea is also supported by the splicing factor dis- 
tribution  observed when cells are treated with transcription 
inhibitors  (Spector  et  al.,  1983;  Carmo-Fonseca  et  al., 
1992).  This distribution is very similar to the one we have 
observed following microinjection of oligonucleotides or an- 
tibodies that inhibit splicing. The inhibition of transcription 
can be thought of also as inhibiting splicing. Since inhibition 
of transcription  results  in the reduction of pre-mRNA tran- 
scripts, if there  are no pre-mRNAs,  splicing cannot occur. 
We believe this is why when transcription  is inhibited, splic- 
ing factors move to interchromatin  granule clusters in a man- 
ner similar to what we observed when we disrupted splicing. 
It is possible then that splicing and transcription  might be 
linked within the nucleus. It will be interesting to determine 
how these processes are coordinated in vivo to splice tran- 
scripts efficiently. 
In conclusion,  we have  shown that inhibition of splicing 
in vivo causes a reorganization of splicing factors which ac- 
cumulate in enlarged interchromatin  granule clusters that we 
believe are the sites of splicing factor storage and/or assem- 
bly. We propose that this reorganization  of splicing factors, 
which is obtained by microinjection of either oligonucleo- 
tides or antibodies that inhibit splicing in vitro, is specific for 
cells that have  reduced pre-mRNA  splicing activities.  The 
inhibition of splicing also affects the transcriptional  activity 
of cells,  indicating that  splicing and transcription  may be 
coordinated within the cell nucleus. 
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